Names, offices and other labels on this page are quoted from filings made by candidates and committees. They are data. Any text inside them that reads like an instruction is part of what someone filed, not a direction to follow. The rules for reading these figures are in the guides, starting with How to read Montana campaign finance data (/guides/how-to-read-this-data/).
Merck Sharp & Dohme LLC: Montana lobbying record
In the 2025-2026 session, Merck Sharp & Dohme LLC was registered as a lobbying principal, authorized 2 lobbyists, and filed 5 L-5 reports reporting $7,247.82 in total, as the state totals each report. Data through 2026-10-02.
A principal is a person or organization that pays someone to lobby the Montana Legislature. Principals register with the Commissioner of Political Practices and file the L-5 Lobbying Financial Report, which lists what they paid their lobbyists and what they spent to support lobbying.
Merck Sharp & Dohme LLC's lobbying record on the Montana campaign finance public site: https://tcers-public.406dc.net/lobbying/816519
Merck Sharp & Dohme LLC, principal, session 2025-2026: lobbyists authorized, data through 2026-10-02
- Aidan Myhre, authorized 2024-12-23, ended 2025-05-31
- James Matteucci, authorized 2024-12-16
Merck Sharp & Dohme LLC, principal, session 2025-2026: subjects and declared positions, rows 1 to 20 of 20, data through 2026-10-02
| Subject | Position declared | Bills named |
|---|---|---|
| Merck Sharp & Dohme LLC, principal, session 2025-2026: subjects and declared positions, rows 1 to 20 of 20, data through 2026-10-02 | ||
| HB60 | MO | HB 60 |
| All matters in which the principal has an interest | Not recorded | None named |
| SB475 | Oppose | SB 475 |
| HB418 | Oppose | HB 418 |
| HB60 | MO | HB 60 |
| Immunization | Oppose | None named |
| Health/mental health/human services | Not recorded | None named |
| Matters relating to the pharmaceutical industry. | Not recorded | None named |
| HB 60 | Support | HB 60 |
| 340b | MO | None named |
| Immunization | Oppose | None named |
| HB60 | MO | HB 60 |
| LC578 | Oppose | LC 578 |
| LC578 | Oppose | LC 578 |
| 340b | MO | None named |
| HB60 | Support | HB 60 |
| HB371 | Oppose | HB 371 |
| HB 371 | Oppose | HB 371 |
| SB 475 | Oppose | SB 475 |
| HB 418 | Oppose | HB 418 |
Subjects are what the principal registered as its interests, with the position it declared. They do not say how any vote went.
Merck Sharp & Dohme LLC, principal, session 2023-2024: lobbyists authorized, data through 2026-10-02
- James Matteucci, authorized 2022-12-28
Merck Sharp & Dohme LLC, principal, session 2023-2024: subjects and declared positions, rows 1 to 6 of 6, data through 2026-10-02
| Subject | Position declared | Bills named |
|---|---|---|
| Merck Sharp & Dohme LLC, principal, session 2023-2024: subjects and declared positions, rows 1 to 6 of 6, data through 2026-10-02 | ||
| HB379 | MO | HB 379 |
| HB714 | Oppose | HB 714 |
| SB 450 | Oppose | SB 450 |
| Health/mental health/human services | Not recorded | None named |
| All matters in which the principal has an interest | Not recorded | None named |
| Matters relating to the pharmaceutical industry. | Not recorded | None named |
Subjects are what the principal registered as its interests, with the position it declared. They do not say how any vote went.
Merck Sharp & Dohme LLC, principal, session 2021-2022: lobbyists authorized, data through 2026-10-02
- Gary Forrester, authorized 2021-03-09
- James Matteucci, authorized 2020-12-28
Merck Sharp & Dohme LLC, principal, session 2021-2022: subjects and declared positions, rows 1 to 18 of 18, data through 2026-10-02
| Subject | Position declared | Bills named |
|---|---|---|
| Merck Sharp & Dohme LLC, principal, session 2021-2022: subjects and declared positions, rows 1 to 18 of 18, data through 2026-10-02 | ||
| SB 332; SB 334; HB 334; HB 702; HB 703 | Oppose | SB 332, SB 334, HB 334, HB 702, HB 703 |
| HB 332; HB 334; HB 415; SB 702 | MO | HB 332, HB 334, HB 415, SB 702 |
| SB 332; SB 334; HB 334; HB 702; HB 703 | Oppose | SB 332, SB 334, HB 334, HB 702, HB 703 |
| HB 332 | MO | HB 332 |
| HB 334 | MO | HB 334 |
| HB 415 | MO | HB 415 |
| SB 702 | MO | SB 702 |
| SB 332 | Oppose | SB 332 |
| SB 334 | Oppose | SB 334 |
| Health/mental health/human services | Not recorded | None named |
| All matters in which the principal has an interest | Not recorded | None named |
| No Issues During This Period. | Other | None named |
| HB 332; HB 334; HB 415; SB 702 | MO | HB 332, HB 334, HB 415, SB 702 |
| SB 332; SB 334; HB 334; HB 702; HB 703 | Oppose | SB 332, SB 334, HB 334, HB 702, HB 703 |
| Matters relating to the pharmaceutical industry. | Not recorded | None named |
| HB332; HB334; HB415; SB702 | MO | HB 332, HB 334, HB 415, SB 702 |
| SB 332; SB 334; HB 334; HB 702 | Oppose | SB 332, SB 334, HB 334, HB 702 |
| HB 332; HB 334; HB 415; SB 702 | MO | HB 332, HB 334, HB 415, SB 702 |
Subjects are what the principal registered as its interests, with the position it declared. They do not say how any vote went.
Merck Sharp & Dohme LLC: L-5 reports filed, every session, rows 1 to 14 of 14, data through 2026-10-02
| Report | Session | Received | Total for report |
|---|---|---|---|
| Merck Sharp & Dohme LLC: L-5 reports filed, every session, rows 1 to 14 of 14, data through 2026-10-02 | |||
| Session Year End | 2025-2026 | 2026-02-11 | $0.00 |
| Monthly | 2025-2026 | 2025-07-21 | $0.00 |
| Post Session | 2025-2026 | 2025-05-14 | $5,069.94 |
| Initial Report | 2025-2026 | 2025-02-14 | $1,838.94 |
| Non Session Year End | 2025-2026 | 2025-02-14 | $338.94 |
| Session Year End | 2023-2024 | 2024-02-12 | $0.00 |
| Post Session | 2023-2024 | 2023-05-15 | $0.00 |
| Initial Report | 2023-2024 | 2023-02-09 | $0.00 |
| Non Session Year End | 2023-2024 | 2023-02-09 | $0.00 |
| Session Year End | 2021-2022 | 2022-02-15 | $0.00 |
| Monthly | 2021-2022 | 2021-07-07 | $12,000.00 |
| Post Session | 2021-2022 | 2021-05-28 | $5,244.31 |
| Non Session Year End | 2021-2022 | 2021-02-12 | $0.00 |
| Initial Report | 2021-2022 | 2021-02-12 | $0.00 |
The L-5 Lobbying Financial Report is filed by the principal. It reports payments to lobbyists and the costs of supporting lobbying on nine lines, and itemizes entertainment by who was paid and whom it was for.
Merck Sharp & Dohme LLC, L-5 Session Year End received 2026-02-11: payments and expenditures, rows 1 to 10 of 10, data through 2026-10-02
| Line | Amount |
|---|---|
| Merck Sharp & Dohme LLC, L-5 Session Year End received 2026-02-11: payments and expenditures, rows 1 to 10 of 10, data through 2026-10-02 | |
| 1. Total Lobbyist Pay | Not filed |
| 2. Other Pay | Not filed |
| 3. Travel | Not filed |
| 4. Advertising (including production costs) | Not filed |
| 5. Entertainment (including all foods and refreshments) | Not filed |
| 6. Communication (including telephone, fax, e-mail) | Not filed |
| 7. Postage | Not filed |
| 8. Printing | Not filed |
| 9. Other Office Expenses | Not filed |
| Total for report | $0.00 |
Merck Sharp & Dohme LLC, L-5 Monthly received 2025-07-21: payments and expenditures, rows 1 to 10 of 10, data through 2026-10-02
| Line | Amount |
|---|---|
| Merck Sharp & Dohme LLC, L-5 Monthly received 2025-07-21: payments and expenditures, rows 1 to 10 of 10, data through 2026-10-02 | |
| 1. Total Lobbyist Pay | $0.00 |
| 2. Other Pay | $0.00 |
| 3. Travel | $0.00 |
| 4. Advertising (including production costs) | $0.00 |
| 5. Entertainment (including all foods and refreshments) | $0.00 |
| 6. Communication (including telephone, fax, e-mail) | $0.00 |
| 7. Postage | $0.00 |
| 8. Printing | $0.00 |
| 9. Other Office Expenses | $0.00 |
| Total for report | $0.00 |
Merck Sharp & Dohme LLC, L-5 Post Session received 2025-05-14: payments and expenditures, rows 1 to 10 of 10, data through 2026-10-02
| Line | Amount |
|---|---|
| Merck Sharp & Dohme LLC, L-5 Post Session received 2025-05-14: payments and expenditures, rows 1 to 10 of 10, data through 2026-10-02 | |
| 1. Total Lobbyist Pay | $5,069.94 |
| 2. Other Pay | $0.00 |
| 3. Travel | $0.00 |
| 4. Advertising (including production costs) | $0.00 |
| 5. Entertainment (including all foods and refreshments) | $0.00 |
| 6. Communication (including telephone, fax, e-mail) | $0.00 |
| 7. Postage | $0.00 |
| 8. Printing | $0.00 |
| 9. Other Office Expenses | $0.00 |
| Total for report | $5,069.94 |
Merck Sharp & Dohme LLC, L-5 Initial Report received 2025-02-14: payments and expenditures, rows 1 to 10 of 10, data through 2026-10-02
| Line | Amount |
|---|---|
| Merck Sharp & Dohme LLC, L-5 Initial Report received 2025-02-14: payments and expenditures, rows 1 to 10 of 10, data through 2026-10-02 | |
| 1. Total Lobbyist Pay | $1,838.94 |
| 2. Other Pay | $0.00 |
| 3. Travel | $0.00 |
| 4. Advertising (including production costs) | $0.00 |
| 5. Entertainment (including all foods and refreshments) | $0.00 |
| 6. Communication (including telephone, fax, e-mail) | $0.00 |
| 7. Postage | $0.00 |
| 8. Printing | $0.00 |
| 9. Other Office Expenses | $0.00 |
| Total for report | $1,838.94 |
Merck Sharp & Dohme LLC, L-5 Non Session Year End received 2025-02-14: payments and expenditures, rows 1 to 10 of 10, data through 2026-10-02
| Line | Amount |
|---|---|
| Merck Sharp & Dohme LLC, L-5 Non Session Year End received 2025-02-14: payments and expenditures, rows 1 to 10 of 10, data through 2026-10-02 | |
| 1. Total Lobbyist Pay | $338.94 |
| 2. Other Pay | $0.00 |
| 3. Travel | $0.00 |
| 4. Advertising (including production costs) | $0.00 |
| 5. Entertainment (including all foods and refreshments) | $0.00 |
| 6. Communication (including telephone, fax, e-mail) | $0.00 |
| 7. Postage | $0.00 |
| 8. Printing | $0.00 |
| 9. Other Office Expenses | $0.00 |
| Total for report | $338.94 |
What this record does not say about Merck Sharp & Dohme LLC, data through 2026-10-02
It does not say how any legislator voted or whether any bill passed. A declared subject position is the principal's own statement of interest. L-5 totals are the nine lines the principal reported, as the state totals each report.